Literature DB >> 28794512

Osteoporosis: Romosozumab versus teriparatide.

Dario Ummarino.   

Abstract

Entities:  

Year:  2017        PMID： 28794512     DOI： 10.1038/nrrheum.2017.135

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  1 in total

1.  Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial.

Authors:  Bente L Langdahl; Cesar Libanati; Daria B Crittenden; Michael A Bolognese; Jacques P Brown; Nadia S Daizadeh; Eva Dokoupilova; Klaus Engelke; Joel S Finkelstein; Harry K Genant; Stefan Goemaere; Lars Hyldstrup; Esteban Jodar-Gimeno; Tony M Keaveny; David Kendler; Peter Lakatos; Judy Maddox; Jorge Malouf; Fabio E Massari; Jose Fernando Molina; Maria Rosa Ulla; Andreas Grauer
Journal:  Lancet       Date:  2017-07-26       Impact factor: 79.321
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.